Welcome : Guest

Rising Incidence of Psychiatric and Neurodegenerative Disorders Drive the Global CNS Therapeutics Market


Published: November 2017

REPORT STATISTICS


  • Code: MCP-1835
  • Pages: 611
  • Tables: 96
  • Companies: 162


CNS THERAPEUTICS: A RESEARCH BRIEF

The global market for CNS Therapeutics is projected to reach US$145 billion by 2024, driven by increasing incidence of CNS disorders, rising acceptance of new therapies and new classes of drugs, aging population and a parallel rise in Parkinsonís and Alzheimerís disease. Other disease conditions propelling increases in CNS prescriptions, although to a lesser extent, include pain manifestations, psychiatric disorders (schizophrenia, sleep disorders, depression and anxiety), cerebrovascular disorders, stroke, seizures, cognitive and memory disorders, and ailments caused due to injuries and physical trauma. The U.S. represents the largest market worldwide, closely followed by Europe. The U.S. market is driven by well-established healthcare infrastructure, increased patient population, and the widespread use of drugs. Significant research and development activities, and the presence of several major pharmaceutical companies in the regions also support market growth. Asia-Pacific represents the fastest growing market with a value CAGR of 3.6% over the analysis period. While factors such as increasing population and rising prevalence of CNS disorders, especially among the 65+ age group, would act as general growth drivers, other factors such as increased focus of governments on improving their healthcare systems would aid market growth in the ensuing years. 

    Summary of Findings

  • Anti-Epilepsy Drugs: The Fastest Growing Market
  • Growing Demand for Combination Therapies Drives Market Growth
  • Introduction of New Alzheimerís Drugs & Neuro Protective Drugs to Support Long-Term Growth
  • Increase in CNS Prescriptions for Pain Manifestations & Psychiatric Disorders to Benefit Demand
  • Patent Expiries of Branded Drugs Offer Opportunities for Generics
  • Growing Healthcare Expenditure in Developing Countries Fuels Growth

    Timeline for Analysis

  • Market Estimates and Forecasts for 2016-2024
  • Historic Review 2011-2015

    Geographic Markets Analyzed

  • US, Canada, Japan, Europe (France, Germany, Italy, UK, Spain, Russia and Rest of Europe), Asia-Pacific (China, India and Rest of Asia-Pacific), Latin America (Brazil and Rest of Latin America), and Rest of World

    Market Segmentation & Classification

  • Product Groups:
    • Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Others

MAJOR PLAYERS

  • AbbVie Inc.
  • Alkermes Plc
  • Allergan, Plc
  • Amneal Pharmaceuticals, LLC
  • AstraZeneca Plc
  • BIAL Group

KEY RESEARCH DELIVERABLES

  • Review of Industry/Market Structure
  • Analysis of Trends & Drivers
  • Insights on Macro Market Scenarios
  • Market SWOT Analysis
  • Latent Demand Forecasts & Projections
  • Comprehensive Geographic Market Analysis
  • Presentation Ready Facts & Statistical Data Findings
  • Coverage of Major/Niche Players, Market Shares & Competition
  • Coverage of major Company/Technology/Product/Financial Stories
  • Extensive Product/Service/End-Use/Technology Coverage Where Applicable







Interested in our research, you can contact our 24/7 Research Support e-Desk at rsd@strategyr.com
or
info411@strategyr.com